| Target Validation Information | |||||
|---|---|---|---|---|---|
| TTD ID | T84486 | ||||
| Target Name | Oxytocin receptor (OTR) | ||||
| Type of Target |
Successful |
||||
| Drug Potency against Target | Carbetocin | Drug Info | Affinity = 7.24+/-0.29 nM | [9] | |
| Drug Info | IC50 = 8500 nM | [4] | |||
| Drug Info | Ki = 37 nM | [3] | |||
| Drug Info | Ki = 997 nM | [3] | |||
| Drug Info | IC50 = 80 nM | [4] | |||
| Drug Info | Ki = 1600 nM | [8] | |||
| Drug Info | Ki = 195 nM | [3] | |||
| Drug Info | Ki = 0.32 nM | [1] | |||
| Drug Info | Ki = 55 nM | [3] | |||
| Drug Info | Ki = 6.24 nM | [1] | |||
| Drug Info | Ki = 826 nM | [3] | |||
| ARGENINE VASOPRESSIN | Drug Info | Ki = 1.17 nM | [3] | ||
| ATOSIBAN | Drug Info | IC50 = 12 nM | [2] | ||
| D(CH2)5[Tyr(Me)2,Thr4,Orn8,Tyr9-NH2]VT | Drug Info | Ki = 0.21 nM | [1] | ||
| DesGly-NH2,d(CH2)5[D-Tyr2,Thr4,Orn8(5/6C-Flu)]VT | Drug Info | Ki = 126 nM | [1] | ||
| D[Arg4,Lys8]VP | Drug Info | Ki = 125 nM | [3] | ||
| D[Arg4,Orn8]VP | Drug Info | Ki = 130 nM | [3] | ||
| D[Arg4]AVP | Drug Info | Ki = 3550 nM | [3] | ||
| D[Cha4,Dab8]VP | Drug Info | Ki = 430 nM | [3] | ||
| D[Cha4,Dap8]VP | Drug Info | Ki = 1200 nM | [3] | ||
| D[Cha4,Lys8]VP | Drug Info | Ki = 590 nM | [3] | ||
| D[Cha4,Orn8]VP | Drug Info | Ki = 550 nM | [3] | ||
| D[Cha4]AVP | Drug Info | Ki = 1430 nM | [3] | ||
| D[Leu4,Dab8]VP | Drug Info | Ki = 41 nM | [3] | ||
| D[Leu4,Dap8]VP | Drug Info | Ki = 134 nM | [3] | ||
| D[Leu4,Lys8]VP | Drug Info | Ki = 64 nM | [3] | ||
| D[Leu4]AVP | Drug Info | Ki = 481 nM | [3] | ||
| D[Lys8(5/6-Flu)]VT | Drug Info | Ki = 0.29 nM | [1] | ||
| D[Orn4,Lys8]VP | Drug Info | Ki = 22 nM | [3] | ||
| D[Orn8(5/6C-Flu)]VT | Drug Info | Ki = 0.25 nM | [1] | ||
| D[Thr4,Lys8(5/6C-Flu)]VT | Drug Info | Ki = 1.8 nM | [1] | ||
| D[Thr4,Orn8(5/6C-Flu)]VT | Drug Info | Ki = 0.4 nM | [1] | ||
| L-371257 | Drug Info | Ki = 19 nM | [8] | ||
| L-372662 | Drug Info | Ki = 14 nM | [8] | ||
| PF-3274167 | Drug Info | Ki = 9.5 nM | [8] | ||
| Retosiban | Drug Info | Ki = 0.65 nM | [6] | ||
| SSR149415 | Drug Info | Ki = 19 nM | [7] | ||
| [Aib7]OT | Drug Info | IC50 = 75 nM | [4] | ||
| [D-Tic7]OT | Drug Info | IC50 = 730 nM | [4] | ||
| [Gly(But)7]OT | Drug Info | IC50 = 1380 nM | [4] | ||
| [HO1][Lys8(5/6C-Flu)]VT | Drug Info | Ki = 0.34 nM | [1] | ||
| [HO1][Orn8(5/6C-Flu)]VT | Drug Info | Ki = 0.18 nM | [1] | ||
| [HO1][Thr4,Orn8(5/6C-Flu)]VT | Drug Info | Ki = 0.17 nM | [1] | ||
| [L-Tic7]OT | Drug Info | IC50 = 130 nM | [4] | ||
| [Lys8(Alexa 488) ]PVA | Drug Info | Ki = 1.04 nM | [5] | ||
| [Lys8(Alexa 546) ]PVA | Drug Info | Ki = 1.95 nM | [5] | ||
| [Mpa1, D-Tic7]OT | Drug Info | IC50 = 380 nM | [4] | ||
| [Mpa1, D-Tyr(Et)2, Aib7, D-Tic9]OT | Drug Info | IC50 = 55 nM | [4] | ||
| [Mpa1, D-Tyr(Et)2, Aib7]OT | Drug Info | IC50 = 485 nM | [4] | ||
| [Mpa1, D-Tyr(Et)2, D-Tic7, D-Tic9]OT | Drug Info | IC50 = 25 nM | [4] | ||
| [Mpa1, D-Tyr(Et)2, D-Tic7]OT | Drug Info | IC50 = 51 nM | [4] | ||
| [Mpa1, D-Tyr(Et)2, Gly(But)3, Gly(But)7]OT | Drug Info | IC50 = 7850 nM | [4] | ||
| [Mpa1, D-Tyr(Et)2, Gly(But)7]OT | Drug Info | IC50 = 1002 nM | [4] | ||
| [Mpa1, D-Tyr(Et)2, L-Tic7]OT | Drug Info | IC50 = 176 nM | [4] | ||
| [Mpa1, D-Tyr(Et)2, Pip7]OT | Drug Info | IC50 = 40 nM | [4] | ||
| [Mpa1, L-Tic7]OT | Drug Info | IC50 = 103 nM | [4] | ||
| [Pip7]OT | Drug Info | IC50 = 7 nM | [4] | ||
| References | |||||
| REF 1 | Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88. | ||||
| REF 2 | Pyridobenzodiazepines: a novel class of orally active, vasopressin V2 receptor selective agonists. Bioorg Med Chem Lett. 2006 Feb 15;16(4):954-9. | ||||
| REF 3 | Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. | ||||
| REF 4 | Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7. Eur J Med Chem. 2007 Jun;42(6):799-806. | ||||
| REF 5 | Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands. J Med Chem. 2007 Oct 4;50(20):4976-85. | ||||
| REF 6 | The discovery of GSK221149A: a potent and selective oxytocin antagonist. Bioorg Med Chem Lett. 2008 Jan 1;18(1):90-4. | ||||
| REF 7 | Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6018-22. | ||||
| REF 8 | Oral oxytocin antagonists. J Med Chem. 2010 Sep 23;53(18):6525-38. | ||||
| REF 9 | [International therapeutic trial comparing the value of radical mastectomy (Halsted) and extended mastectomy (Halsted plus internal mammary node di... Chirurgie. 1976;102(8):638-49. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.